Clinicopathologic significance of claudin-6, occludin, and matrix metalloproteinases −2 expression in ovarian carcinoma

Diagnostic Pathology

Chengshi Quan¹  Jiuxia Li¹  Minlan Yang¹  Min Wang¹  Yuanyuan Liu¹  Yan Lu¹  Xiaowei Zhang¹  Zhijing Liu¹  Dongjing Lin¹  Xiangshu Jin¹  Liping Wang¹ 

[1] The Key Laboratory of Pathobiology, Ministry of Education, College of Basic Medical Sciences, Jilin University, Changchun, Jilin, China

关键词: MMP-2;    Occludin;    Claudin-6;    Ovarian cancer;    Tight junctions;   

Others  :  803880
DOI  :  10.1186/1746-1596-8-190

 received in 2013-08-25, accepted in 2013-11-06,  发布年份 2013

【 摘 要 】

Background

Tight junctions (TJs) are mainly composed of claudins, occludin, and tight junction adhesion molecules (JAM). The invasive and metastatic phenotype of highly invasive cancer cells has been related to abnormal structure and function of TJs, and with expression of activated matrix metalloproteinases (MMPs). The relevance of these mechanisms responsible for the invasion and metastasis of ovarian carcinoma is unclear. Similarly, it is not known if the expression of claudin-6, occludin and MMP2 is related with the clinical properties of these tumors.

Methods

Expression of claudin-6, occludin, and MMP2 was detected in samples of human ovarian cancer tissues by immunohistochemistry and correlated with the clinical properties of the tumors.

Results

The positive expression rates of claudin-6 and MMP-2 were higher in ovarian papillary serous carcinomas than n ovarian serous adenomas (P < 0.05). There were no differences in the expression of occludin (P > 0.05). The expression of claudin-6 and occludin in ovarian cancer was not correlated with patient age, pathological grade, clinical stage, and metastasis (P > 0.05). MMP-2 expression was enhanced with increased clinical stage and metastasis (P < 0.05), but was unrelated to patient age or tumor grade (P > 0.05). There were no apparent correlations between expression of claudin-6, occludin and MMP-2 in ovarian cancer tissue (P > 0.05).

Conclusions

Our data suggest, for the first time, that the claudin-6 and MMP-2 are up-regulated in ovarian papillary serous carcinomas, MMP-2 expression was enhanced with increased clinical stage and metastasis. Claudin-6 and MMP-2 may play a positive role in the invasion and metastasis of ovarian cancer.

Virtual slides

The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1775628454106511 webcite.

【 授权许可】

   
2013 Wang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Egeberg DL, Lethan M, Manguso R, Schneider L, Awan A, Jorgensen TS, Byskov AG, Pedersen LB, Christensen ST: Primary cilia and aberrant cell signaling in epithelial ovarian cancer. Cilia 2012, 1:15. BioMed Central Full Text
• [2]Waldemarson S, Krogh M, Alaiya A, Kirik U, Schedvins K, Auer G, Hansson KM, Ossola R, Aebersold R, Lee H, et al.: Protein expression changes in ovarian cancer during the transition from benign to malignant. J Proteome Res 2012, 11:2876-2889.
• [3]Itoh M, Bissell MJ: The organization of tight junctions in epithelia: implications for mammary gland biology and breast tumorigenesis. J Mammary Gland Biol Neoplasia 2003, 8:449-462.
• [4]Gonzalez-Mariscal L, Lechuga S, Garay E: Role of tight junctions in cell proliferation and cancer. Prog Histochem Cytochem 2007, 42:1-57.
• [5]Agarwal R, D’Souza T, Morin PJ: Claudin-3 and claudin-4 expression in ovarian epithelial cells enhances invasion and is associated with increased matrix metalloproteinase-2 activity. Cancer Res 2005, 65:7378-7385.
• [6]Kominsky SL, Vali M, Korz D, Gabig TG, Weitzman SA, Argani P, Sukumar S: Clostridium perfringens enterotoxin elicits rapid and specific cytolysis of breast carcinoma cells mediated through tight junction proteins claudin 3 and 4. Am J Pathol 2004, 164:1627-1633.
• [7]Nichols LS, Ashfaq R, Iacobuzio-Donahue CA: Claudin 4 protein expression in primary and metastatic pancreatic cancer: support for use as a therapeutic target. Am J Clin Pathol 2004, 121:226-230.
• [8]Resnick MB, Gavilanez M, Newton E, Konkin T, Bhattacharya B, Britt DE, Sabo E, Moss SF: Claudin expression in gastric adenocarcinomas: a tissue microarray study with prognostic correlation. Hum Pathol 2005, 36:886-892.
• [9]de Oliveira SS, de Oliveira IM, De Souza W, Morgado-Diaz JA: Claudins upregulation in human colorectal cancer. FEBS Lett 2005, 579:6179-6185.
• [10]Martin TA, Jiang WG: Tight junctions and their role in cancer metastasis. Histol Histopathol 2001, 16:1183-1195.
• [11]Miyamori H, Takino T, Kobayashi Y, Tokai H, Itoh Y, Seiki M, Sato H: Claudin promotes activation of pro-matrix metalloproteinase-2 mediated by membrane-type matrix metalloproteinases. J Biol Chem 2001, 276:28204-28211.
• [12]Oku N, Sasabe E, Ueta E, Yamamoto T, Osaki T: Tight junction protein claudin-1 enhances the invasive activity of oral squamous cell carcinoma cells by promoting cleavage of laminin-5 gamma2 chain via matrix metalloproteinase (MMP)-2 and membrane-type MMP-1. Cancer Res 2006, 66:5251-5257.
• [13]Lu Z, Lu N, Li C, Li F, Zhao K, Lin B, Guo Q: Oroxylin A inhibits matrix metalloproteinase-2/9 expression and activation by up-regulating tissue inhibitor of metalloproteinase-2 and suppressing the ERK1/2 signaling pathway. Toxicol Lett 2012, 209:211-220.
• [14]Sims JD, McCready J, Jay DG: Extracellular heat shock protein (Hsp)70 and Hsp90alpha assist in matrix metalloproteinase-2 activation and breast cancer cell migration and invasion. PLoS One 2011, 6:e18848.
• [15]Zeng ZS, Cohen AM, Guillem JG: Loss of basement membrane type IV collagen is associated with increased expression of metalloproteinases 2 and 9 (MMP-2 and MMP-9) during human colorectal tumorigenesis. Carcinogenesis 1999, 20:749-755.
• [16]Lippoldt A, Liebner S, Andbjer B, Kalbacher H, Wolburg H, Haller H, Fuxe K: Organization of choroid plexus epithelial and endothelial cell tight junctions and regulation of claudin-1, -2 and −5 expression by protein kinase C. Neuroreport 2000, 11:1427-1431.
• [17]Martin TA, Jiang WG: Loss of tight junction barrier function and its role in cancer metastasis. Biochim Biophys Acta 2009, 1788:872-891.
• [18]Miyoshi J, Takai Y: Molecular perspective on tight-junction assembly and epithelial polarity. Adv Drug Deliv Rev 2005, 57:815-855.
• [19]Pan XY, Wang B, Che YC, Weng ZP, Dai HY, Peng W: Expression of claudin-3 and claudin-4 in normal, hyperplastic, and malignant endometrial tissue. Int J Gynecol Cancer 2007, 17:233-241.
• [20]Long H, Crean CD, Lee WH, Cummings OW, Gabig TG: Expression of clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in prostate cancer epithelium. Cancer Res 2001, 61:7878-7881.
• [21]Banan A, Zhang LJ, Shaikh M, Fields JZ, Farhadi A, Keshavarzian A: Theta-isoform of PKC is required for alterations in cytoskeletal dynamics and barrier permeability in intestinal epithelium: a novel function for PKC-theta. Am J Physiol Cell Physiol 2004, 287:C218-C234.
• [22]Aldred MA, Huang Y, Liyanarachchi S, Pellegata NS, Gimm O, Jhiang S, Davuluri RV, de la Chapelle A, Eng C: Papillary and follicular thyroid carcinomas show distinctly different microarray expression profiles and can be distinguished by a minimum of five genes. J Clin Oncol 2004, 22:3531-3539.
• [23]Rangel LB, Agarwal R, D’Souza T, Pizer ES, Alo PL, Lancaster WD, Gregoire L, Schwartz DR, Cho KR, Morin PJ: Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas. Clin Cancer Res 2003, 9:2567-2575.
• [24]Resnick MB, Konkin T, Routhier J, Sabo E, Pricolo VE: Claudin-1 is a strong prognostic indicator in stage II colonic cancer: a tissue microarray study. Mod Pathol 2005, 18:511-518.
• [25]Kominsky SL, Argani P, Korz D, Evron E, Raman V, Garrett E, Rein A, Sauter G, Kallioniemi OP, Sukumar S: Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast. Oncogene 2003, 22:2021-2033.
• [26]Wu Q, Liu Y, Ren Y, Xu X, Yu L, Li Y, Quan C: Tight junction protein, claudin-6, downregulates the malignant phenotype of breast carcinoma. Eur J Cancer Prev 2010, 19:186-194.
• [27]Xu X, Jin H, Liu Y, Liu L, Wu Q, Guo Y, Yu L, Liu Z, Zhang T, Zhang X, et al.: The expression patterns and correlations of claudin-6, methy-CpG binding protein 2, DNA methyltransferase 1, histone deacetylase 1, acetyl-histone H3 and acetyl-histone H4 and their clinicopathological significance in breast invasive ductal carcinomas. Diagn Pathol 2012, 7:33. BioMed Central Full Text
• [28]Lin Z, Zhang X, Liu Z, Liu Q, Wang L, Lu Y, Liu Y, Wang M, Yang M, Jin X, Quan C: The distinct expression patterns of claudin-2, -6, and −11 between human gastric neoplasms and adjacent non-neoplastic tissues. Diagn Pathol 2013, 8:133. BioMed Central Full Text
• [29]Ando-Akatsuka Y, Saitou M, Hirase T, Kishi M, Sakakibara A, Itoh M, Yonemura S, Furuse M, Tsukita S: Interspecies diversity of the occludin sequence: cDNA cloning of human, mouse, dog, and rat-kangaroo homologues. J Cell Biol 1996, 133:43-47.
• [30]Orban E, Szabo E, Lotz G, Kupcsulik P, Paska C, Schaff Z, Kiss A: Different expression of occludin and ZO-1 in primary and metastatic liver tumors. Pathol Oncol Res 2008, 14:299-306.
• [31]Tobioka H, Isomura H, Kokai Y, Tokunaga Y, Yamaguchi J, Sawada N: Occludin expression decreases with the progression of human endometrial carcinoma. Hum Pathol 2004, 35:159-164.
• [32]Busch C, Hanssen TA, Wagener C, OBrink B: Down-regulation of CEACAM1 in human prostate cancer: correlation with loss of cell polarity, increased proliferation rate, and Gleason grade 3 to 4 transition. Hum Pathol 2002, 33:290-298.
• [33]Osanai M, Murata M, Nishikiori N, Chiba H, Kojima T, Sawada N: Epigenetic silencing of occludin promotes tumorigenic and metastatic properties of cancer cells via modulations of unique sets of apoptosis-associated genes. Cancer Res 2006, 66:9125-9133.
• [34]Rouach N, Pebay A, Meme W, Cordier J, Ezan P, Etienne E, Giaume C, Tence M: S1P inhibits gap junctions in astrocytes: involvement of G and Rho GTPase/ROCK. Eur J Neurosci 2006, 23:1453-1464.
• [35]Campo E, Merino MJ, Tavassoli FA, Charonis AS, Stetler-Stevenson WG, Liotta LA: Evaluation of basement membrane components and the 72 kDa type IV collagenase in serous tumors of the ovary. Am J Surg Pathol 1992, 16:500-507.
• [36]van ’t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, et al.: Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536.
• [37]Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB, Gerald WL, Massague J: Genes that mediate breast cancer metastasis to lung. Nature 2005, 436:518-524.
• [38]Autio-Harmainen H, Karttunen T, Hurskainen T, Hoyhtya M, Kauppila A, Tryggvason K: Expression of 72 kilodalton type IV collagenase (gelatinase A) in benign and malignant ovarian tumors. Lab Invest 1993, 69:312-321.
• [39]Parsons SL, Watson SA, Collins HM, Griffin NR, Clarke PA, Steele RJ: Gelatinase (MMP-2 and −9) expression in gastrointestinal malignancy. Br J Cancer 1998, 78:1495-1502.
• [40]Kleiner DE, Stetler-Stevenson WG: Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol 1999, 43(Suppl):S42-S51.
• [41]Giannelli G, Falk-Marzillier J, Schiraldi O, Stetler-Stevenson WG, Quaranta V: Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science 1997, 277:225-228.
• [42]Li HC, Cao DC, Liu Y, Hou YF, Wu J, Lu JS, Di GH, Liu G, Li FM, Ou ZL, et al.: Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma. Breast Cancer Res Treat 2004, 88:75-85.
• [43]Katoh T, Yasuda M, Hasegawa K, Kozawa E, Maniwa J, Sasano H: Estrogen-producing endometrioid adenocarcinoma resembling sex cord-stromal tumor of the ovary: a review of four postmenopausal cases. Diagn Pathol 2012, 7:164. BioMed Central Full Text
• [44]Asher V, Khan R, Warren A, Shaw R, Schalkwyk GV, Bali A, Sowter HM: The eag potassium channel as a new prognostic marker in ovarian cancer. Diagn Pathol 2010, 5:78. BioMed Central Full Text
• [45]Ozer H, Yenicesu G, Arici S, Cetin M, Tuncer E, Cetin A: Immunohistochemistry with apoptotic-antiapoptotic proteins (p53, p21, bax, bcl-2), c-kit, telomerase, and metallothionein as a diagnostic aid in benign, borderline, and malignant serous and mucinous ovarian tumors. Diagn Pathol 2012, 7:124. BioMed Central Full Text
• [46]Sundov D, Caric A, Mrklic I, Gugic D, Capkun V, Hofman ID, Mise BP, Tomic S: P53, MAPK, topoisomerase II alpha and Ki67 immunohistochemical expression and KRAS/BRAF mutation in ovarian serous carcinomas. Diagn Pathol 2013, 8:21. BioMed Central Full Text